T ranscatheter aortic valve replacement (TAVR) has revolutionized the treatment of symptomatic patients with severe aortic stenosis. Since the first of these procedures was performed in 2002 and U.S. Food and Drug Administration approval was received in 2011, indications have expanded to include progressively younger and lower risk patients, and TAVR volume has been increasing exponentially. It is the tremendous friction force of the metallic stent frame against the calcification of the native valve, prevalent in patients with degenerative calcific aortic stenosis, which serves as the anchor for these suture-less balloon-expandable or self-expanding bioprostheses. Off-label applications of the procedure are now being expanded to patients without heavy calcification, including those with failed surgically implanted bioprostheses; bicuspid aortic valves; and, the subject of the paper in this issue of the Journal, pure aortic regurgitation (AR).

中文翻译：

---

用于严重主动脉瓣反流的 TAVR

经导管主动脉瓣置换术 (TAVR) 彻底改变了有症状的严重主动脉瓣狭窄患者的治疗。自 2002 年首次实施这些手术并于 2011 年获得美国食品和药物管理局的批准以来，适应症已扩大到包括逐渐年轻化和风险较低的患者，并且 TAVR 量呈指数增长。正是金属支架框架对天然瓣膜钙化产生的巨大摩擦力，在退行性钙化性主动脉狭窄患者中普遍存在，作为这些无缝线球囊扩张或自扩张生物假体的锚固件。该程序的标签外应用现在正在扩展到没有严重钙化的患者，包括那些手术植入生物假体失败的患者；二叶主动脉瓣；以及本期期刊论文的主题，纯主动脉瓣关闭不全 (AR)。